Skip to main content
S

Sansimeon

Sansimeon provides scalable single‑cell sequencing and immune profiling services that generate high‑resolution, multi‑modal datasets—including T‑cell receptor repertoires and genome‑wide CRISPR screens—for pharmaceutical and biotech companies.

San Carlos, United StatesFounded 20213300+ followers
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Pharma and biotech companies often lack scalable, high‑resolution single‑cell and immune profiling capabilities, making it difficult to generate the large, multi‑modal datasets needed for AI‑driven biomarker discovery, target identification, and efficient clinical trial design.

Solution

Sansimeon offers a suite of scalable single‑cell sequencing and immune profiling services that produce genome‑wide CRISPR screening data and detailed T‑cell receptor repertoire profiles. By processing complex clinical samples in a cost‑effective, streamlined workflow, the platform delivers high‑resolution, multi‑modal datasets that can be directly integrated into machine‑learning pipelines. These data enable personalized cancer therapy design, accelerate the development of CRISPR‑based therapeutics, and support the identification of disease biomarkers and therapeutic targets. Additionally, Sansimeon provides analytical support to translate single‑cell insights into optimized clinical trial designs and drug discovery strategies.

Target Audience

Primary customers are pharmaceutical and biotechnology companies seeking advanced single‑cell and immune profiling data to inform drug discovery, biomarker development, and clinical trial optimization.

Features

  • Scalable single‑cell RNA‑seq pipelines capable of handling large patient cohorts
  • Integrated TCR repertoire profiling for comprehensive immune response characterization
  • Genome‑wide CRISPR screening services to identify functional gene targets
  • Multi‑modal data generation (transcriptomic, epigenomic, proteomic) for AI‑ready datasets
  • End‑to‑end data analysis pipelines that produce machine‑learning‑compatible outputs
  • Support for personalized cancer therapy design based on individual immune signatures
  • Turnkey processing of complex clinical samples with reduced cost and turnaround time
This profile is AI-generated and may contain inaccuracies.